(0.74%) 5 120.00 points
(0.10%) 38 328 points
(1.03%) 17 749 points
(0.72%) $84.17
(-5.07%) $1.555
(0.68%) $2 358.40
(0.87%) $27.59
(0.49%) $925.00
(0.10%) $0.933
(0.38%) $10.99
(-0.05%) $0.799
(-0.48%) $91.73
Live Chart Being Loaded With Signals
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China...
Stats | |
---|---|
Today's Volume | 1.53M |
Average Volume | 1.71M |
Market Cap | 2.28B |
EPS | HKD0 ( 2024-03-11 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -4.56 |
ATR14 | HKD0.00600 (0.18%) |
Volume Correlation
Abbisko Cayman Limited Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abbisko Cayman Limited Correlation - Currency/Commodity
Abbisko Cayman Limited Financials
Annual | 2023 |
Revenue: | HKD19.06M |
Gross Profit: | HKD19.06M (100.00 %) |
EPS: | HKD-0.670 |
FY | 2023 |
Revenue: | HKD19.06M |
Gross Profit: | HKD19.06M (100.00 %) |
EPS: | HKD-0.670 |
FY | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD0 |
FY | 2022 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD-0.800 |
Financial Reports:
No articles found.
Abbisko Cayman Limited
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators